Perrigo PPA Product Withdrawal Costs Could Reach $19 Mil.

FDA's request that drug companies voluntarily withdraw phenylpropanolamine-containing cough/cold remedies and appetite suppressants from the market is expected to have no significant, long-term financial impact on two major private labelers who are now reformulating products.

More from Archive

More from Pink Sheet